Stockreport

Nasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epinephrine Powder at AAAAI 2026

Nasus Pharma Ltd. Ordinary Shares  (NSRX) 
PDF TEL AVIV, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the de [Read more]